Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Investigación financiada por OMF: Deformidad de los glóbulos rojos en EM/SFC

En este #OMFScienceWednesday, presentamos un nuevo proyecto que OMF está financiando que evaluará la «deformabilidad» de los glóbulos rojos como un posible biomarcador para EM/ FC.

Los glóbulos rojos son las células más comunes en la sangre. Su función principal es transportar oxígeno y dióxido de carbono en la sangre, y este papel depende en parte de su «deformabilidad» / elasticidad a medida que fluyen a través de pequeños vasos sanguíneos. Las alteraciones en la deformabilidad de los glóbulos rojos se han asociado con inflamación y enfermedades como la sepsis, y algunos estudios sugieren que esta alteración en la deformabilidad de los glóbulos rojos ocurre en EM/SFC. Estas observaciones junto con la nueva tecnología disponible para medir la deformabilidad de los glóbulos rojos, hicieron que el equipo del Dr. Ron Davis en Stanford y sus colaboradores en la Universidad Estatal de San José examinaran la deformabilidad en EM/SFC.

En algunos datos muy recientes generados por este equipo, hay indicios de que la deformabilidad de los glóbulos rojos está reducida en pacientes con EM/SFC. Los glóbulos rojos en EM/SFC parecen moverse más lentamente y elongarse menos que los controles sanos, según las pruebas hechas con esta nueva tecnología. Estamos financiando un proyecto para confirmar estos hallazgos en más pacientes y para estudiar los glóbulos rojos usando métodos adicionales, que incluyen varios tipos de microscopía avanzada, para comprender mejor por qué existen estas diferencias. 

Si estos experimentos tienen éxito, ¡pueden establecer un nuevo biomarcador para EM/SFC que podría ayudar en el diagnóstico y posiblemente encontrar nuevos tratamientos! Mantente en contacto para conocer más.

Obtenga más información sobre la deformabilidad de los glóbulos rojos en este video de Khan Academy:


OMF agradece esta traducción a María Cuesta

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.


In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.


The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.


About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.


Heather Ah San

Development and Communications Manager